Company Filing History:
Years Active: 2007-2010
Title: Enno Schweinberger - Innovator in Nucleic Acid Technologies
Introduction
Enno Schweinberger, an inventive mind hailing from Oberweser, Germany, has made significant contributions in the field of nucleic acid technologies. With a total of three patents to his name, Schweinberger has focused on advancing the stability and functionality of oligonucleotides through innovative compounds.
Latest Patents
Among his latest inventions are the patents concerning 2-azapurine compounds and their use within oligonucleotides. Notably, the 2-azapurine and especially the 2-azaadenine bases form specific base pairs with guanine. This pairing exhibits stability comparable to that of adenine-thymine but is less stable than guanine-cytosine. By incorporating 2-azaadenine residues into oligonucleotides in place of cytosine, these compounds lead to hybridization complexes with nucleic acids that maintain homogeneous stability. This innovation is particularly valuable in adapting the stabilities of various oligonucleotide sequences for numerous hybridization techniques, including oligomer chip technology.
Career Highlights
Throughout his career, Schweinberger has worked with prominent organizations in the biomedical field, including Roche Diagnostics GmbH and Roche Molecular Systems, Inc. These companies have provided him with a vibrant platform to explore and implement his inventive ideas.
Collaborations
Enno Schweinberger has collaborated with distinguished colleagues such as Frank Seela and Dieter Heindl. These partnerships have enabled him to enhance his research and contribute to the advancement of innovations in nucleic acid technologies.
Conclusion
Enno Schweinberger continues to be a pivotal figure in the realm of oligonucleotides and nucleic acid stability. His innovative patents and collaborations reflect his dedication to enhancing technology in the field, making a lasting impact on scientific research and applications.